Bing Yao
-
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug
ArriVent BioPharma in Newtown Square is working on a deal potentially worth more than $1 billion to acquire the rights for an experimental gastrointestinal cancer…
-
Newtown Square’s ArriVent Partners With Chinese Firm on Cancer Drug
ArriVent Biopharma in Newtown Square has made a deal valued up to $615 million with a Chinese firm on a cancer drug development, writes John…
-
Newtown Square’s Arrivent Plans Public Stock Offering to Fund Cancer Drug
ArriVent Biopharma in Newtown Square plans to initiate a public stock offering to raise between $137.5 million and $160 million for the development and launch…
-
Newtown Square’s ArriVent Has Stock Sale for Cancer Drug
A Newtown Square biopharmaceutical company, ArriVent, has raised $110 million in a private stock sale to bring cancer medicines approved in China to the U.S.…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
